Abstract
Fluvastatin treatment in patients with average cholesterol levels undergoing their first successful PCI significantly reduces the risk of major adverse cardiac events.
Keywords
MedicineMaceConventional PCIFluvastatinPercutaneous coronary interventionMyocardial infarctionPlaceboInternal medicineRandomized controlled trialCardiologyAnginaSurgerySimvastatin
Affiliated Institutions
Related Publications
Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention
Routine measurement of FFR in patients with multivessel coronary artery disease who are undergoing PCI with drug-eluting stents significantly reduces the rate of the composite e...
Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE>
For patients with acute coronary syndrome, lipid-lowering therapy with atorvastatin, 80 mg/d, reduces recurrent ischemic events in the first 16 weeks, mostly recurrent symptomat...
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention
Following PCI, long-term (1-year) clopidogrel therapy significantly reduced the risk of adverse ischemic events. A loading dose of clopidogrel given at least 3 hours before the ...
Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics<SUBTITLE>The PCI-CLARITY Study</SUBTITLE>
Clopidogrel pretreatment significantly reduces the incidence of cardiovascular death or ischemic complications both before and after PCI and without a significant increase in ma...
Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction
Background— Although clopidogrel reduces the risk of cardiovascular episodes after coronary events and stenting, a substantial number of incidents continue to occur. Methods and...
Publication Info
- Year
- 2002
- Type
- article
- Volume
- 287
- Issue
- 24
- Pages
- 3215-3215
- Citations
- 709
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
709
OpenAlex
Cite This
Patrick W. Serruys
(2002).
Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>.
JAMA
, 287
(24)
, 3215-3215.
https://doi.org/10.1001/jama.287.24.3215
Identifiers
- DOI
- 10.1001/jama.287.24.3215